New data 📝 At #EHA2025 and #18ICML, Matthew Ku and Krish Patel, respectively, presented results from a phase Ib study investigating JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in patients with R/R LBCL.
Learn more: https://loom.ly/bobViGE
#Lymphoma #lymsm #MedNews #MedEd
#WorldLymphomaAwarenessDay🩸🌎
Hear as Andrew Evens highlights the significant advancements made in the treatment of both early-stage and advanced-stage #HodgkinLymphoma:
🎥 👉 buff.ly/sBXRjT9
#Lymphoma #LYMsm #HemOnc #Hematology #18ICML #CTSM #HemeSky #MedSky #BloodSky
📝 During the Lymphoma Hub symposium at #18ICML, titled Customizing therapy for MCL, the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the audience.
Listen here: https://loom.ly/PRy_HK4
#Lymphoma #lymsm #MedEd
📝 During the Lymphoma Hub symposium at #18ICML, Michael Wang discussed current therapies for MCL and their combinations.
Listen here: https://loom.ly/b5GWGZU
#Lymphoma #lymsm #MedEd
It was great to catch up with Juan Alderuccio at #18ICML to hear the results from the LOTIS-7 trial of loncastuximab tesirine plus glofitamab in patients with R/R NHL.
Watch the interview here:
👉 buff.ly/n2ldbrC 👈
#LYMsm #Lymphoma #CTSM #TrialUpdate #ImmunoOnc #HemOnc #DLBCL
At #18ICML, Swaminathan Iyer of @mdanderson.bsky.social shared insight into a first-in-human Phase I study of DR-01, a CD94-targeting monoclonal antibody, in patients with R/R cytotoxic T-cell lymphomas.
Click here to find out more:
🎥 buff.ly/MqyhOn4
#LYMsm #Lymphoma #HemOnc #CTSM #TrialUpdate
It's always fantastic to catch up with @drmdavids.bsky.social of @danafarber.bsky.social!😄
At #18ICML, Dr Davids shared insights into the ReVenG trial, evaluating the safety & efficacy of venetoclax plus obinutuzumab retreatment in R/R CLL.
Watch now:
👉 buff.ly/5rzmgND 👈
#CLLsm #Leusm #Leukemia
🎥 Sairah Ahmed of @mdanderson.bsky.social comments on the impact of EBV status on outcomes with nivo-AVD versus BV-AVD in patients with Hodgkin #lymphoma:
👉 buff.ly/vIRBg29 👈
#HodgkinLymphoma #LYMsm #18ICML #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
📝 During the Lymphoma Hub symposium at #18ICML Wojciech Jurczak and the expert panel discussed sequencing therapies and practical management of adverse events in MCL.
Watch the full video here https://loom.ly/xQbmp6c
#Lymphoma #lymsm #MedEd
📝 A Q&A session during the Lymphoma Hub symposium at #18ICML explored factors influencing treatment selection in patients with MCL.
Learn more: https://loom.ly/qdcrsgE
#Lymphoma #lymsm #MedEd
📝 During the Lymphoma Hub symposium at #18ICML Wojciech Jurczak led a case-based presentation and panel discussion on sequencing therapies and practical management of adverse events in MCL.
Listen here https://loom.ly/WcRSPKQ
#Lymphoma #lymsm #MedEd
Are you interested in hearing the interim results of a Phase II trial using zamto-cel, a dual-targeted #CARTCell product, in the treatment of R/R #DLBCL?🩸💉
Then don't miss our interview from #18ICML with Nirav Shah of @medicalcollegeofwi.bsky.social:
👉 buff.ly/NBenyVY 👈
#LYMsm #Lymphoma #CTSM
📝 The Lymphoma Hub symposium “Customizing therapy for MCL” at #18ICML concluded with a Q&A session, where the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the live audience.
Learn more: https://loom.ly/qdcrsgE
#Lymphoma #lymsm #MedEd
What are the key unmet needs in PTCL & what further research is needed in this space?🩸🤔
Tetiana Skrypets shares her thoughts in an interview from #18ICML:
🎥 buff.ly/rh4EWSx
#LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky
What are the differences in managing primary versus secondary CNS #lymphoma?🤔🩸
We asked Nikita Dave of @upenn.edu this in an interview at #18ICML, and here's what she had to say:
👉 buff.ly/D9847uy
#LYMsm #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky
📝 A presentation by Michael Wang during the Lymphoma Hub symposium at #18ICML provided an overview of current therapies and their combinations for patients with MCL.
Learn more: https://loom.ly/hrCsHCY
#Lymphoma #lymsm #MedEd
📝 During the Lymphoma Hub symposium at #18ICML, Michael Wang discussed current therapies for MCL and their combinations.
Learn more: https://loom.ly/hrCsHCY
#Lymphoma #lymsm #MedEd
#18ICML | Neil Berinstein of @sunnybrookhsc.bsky.social shares updates from the BRAWM trial, which is evaluating the combination of bendamustine, rituximab, & acalabrutinib in Waldenström’s macroglobulinemia:
🎥 buff.ly/svYBGt2
#LYMsm #Lymphoma #RareDisease #HemOnc #ImmunoOnc #CTSM #TrialUpdate
Want to hear insights into the real-world effectiveness of covalent BTK inhibitors in the first-line treatment of patients with symptomatic CLL?🩸
Check out our fantastic recent interview from #18ICML with Ryan Jacobs:
👉 buff.ly/7eXwIqV 👈
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky
Hear as Elizabeth Budde of @cityofhope.bsky.social shares the promising results of a Phase II study evaluating mosunetuzumab plus polatuzumab vedotin in pts with R/R #MantleCellLymphoma & high-risk features.
Click here:
🎥 buff.ly/lq9B4hr
#LYMsm #18ICML #CTSM #TrialUpdate #ImmunoOnc #BloodSky
Following #18ICML, we had the pleasure of catching up with Nilanjan Ghosh to hear his highlights in #NonHodgkinLymphoma from this year’s meeting.🩸
Click here for the comprehensive overview:
👉 buff.ly/RQDPS8G
#DLBCL #MantleCellLymphoma #FollicularLymphoma #LYMsm #CTSM #Lymphoma #ImmunoOnc
In an interview from #18ICML, Nikhil Mankuzhy of @mskcancercenter.bsky.social provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4 Gy for indolent #NonHodgkinLymphoma:
🎥 buff.ly/bLGk41w
#LYMsm #Lymphoma #RadOnc #HemOnc #BloodSky #HemeSky #MedSky
What are some of the most exciting developments in the field of Waldenström’s macroglobulinemia?🩸
We caught up with Steven Treon of @danafarber.bsky.social at #18ICML to find out!
Watch the interview here:
👉 buff.ly/WoIXa0k 👈
#LYMsm #Lymphoma #HemOnc #BloodSky #MedSky #HemeSky
Want to hear about the recent publication of the updated LYSA guidelines for the diagnosis and management of primary mediastinal B-cell #lymphoma?🩸
Check out our interview from #18ICML with Vincent Camus:
👉 buff.ly/sFZ0XoZ 👈
#LYMsm #HemOnc #BloodSky #HemeSky #MedSky
Watch our interview from #18ICML to hear about the safety & efficacy of mosunetuzumab treatment in previously untreated #FollicularLymphoma & marginal zone #lymphoma from Adam Olszewski:
🎥 buff.ly/1yymrHB
#LYMsm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
📝 During the Lymphoma Hub symposium at #18ICML, Wojciech Jurczak presented a case-based discussion on sequencing therapies and practical management of adverse events in MCL.
Learn more: https://loom.ly/xQbmp6c
#Lymphoma #lymsm #MedEd
It was a pleasure to speak with Karan Chohan of @mdanderson.bsky.social at #18ICML to hear about the long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy.🩸
Click here to watch the interview:
👉 buff.ly/tKePX7s
#LYMsm #Lymphoma #HemOnc
In a recent interview, Alaa Ali provided valuable insight into selecting between CAR T-cell products for treating LBCL.💉🩸
Click here to learn more:
👉 buff.ly/DLmjhkP 👈
#CARTCell #ImmunoOnc #LYMsm #DLBCL #HemOnc #18ICML #Lymphoma
ICYMI: The presence of certain intratumoral microbes was linked to survival outcomes in #DLBCL, according to findings #18ICML.
sohoinsider.com/meetings-con...
📝 During the Lymphoma Hub symposium at #18ICML Julie Vose discussed the unmet needs in the treatment of MCL.
Watch here: https://loom.ly/zhVtS3s
#Lymphoma #lymsm #MedEd
